Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer

被引：10
|
作者：
Ettl, Johannes [1 ]
机构：
[1] Tech Univ Munich, Dept Obstet & Gynecol, Klinikum Rechts Isar, Munich, Germany
来源：
BREAST CARE | 2016年 / 11卷 / 03期
关键词：
Advanced breast cancer; Palbociclib; CDK4/6; Endocrine therapy; Cell cycle; DEPENDENT KINASE 4/6; 1ST-LINE TREATMENT; SUBGROUP ANALYSIS; LETROZOLE L; PD; 0332991; PALOMA-1/TRIO-18; COMBINATION; TRIAL; EFFICACY; SAFETY;
D O I：
10.1159/000447417
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Palbociclib is the first inhibitor of the cyclin-dependent kinases (CDK) 4 and 6 to be introduced into clinical practice. Preclinical investigations led to its clinical development in advanced hormone receptor (HR)-positive breast cancer. To date, 2 significant clinical trials have been fully published. In this article, the results of these trials and their clinical relevance for the management of HR-positive advanced breast cancer are discussed. (C) 2016 S. Karger GmbH, Freiburg
引用
收藏
页码：174 / 176
页数：3
相关论文
共 50 条
  • [31] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Kim, Esther S.
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2017, 12 (03) : 373 - 383
  • [32] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Esther S. Kim
    Lesley J. Scott
    Targeted Oncology, 2017, 12 : 373 - 383
  • [33] The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
    Saleh, Lubaid
    Ottewell, Penelope D.
    Brown, Janet E.
    Wood, Steve L.
    Brown, Nichola J.
    Wilson, Caroline
    Park, Catherine
    Ali, Simak
    Holen, Ingunn
    CANCERS, 2023, 15 (08)
  • [34] Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer
    Duso, Bruno Achutti
    Trapani, Dario
    Viale, Giulia
    Criscitiello, Carmen
    D'Amico, Paolo
    Belli, Carmen
    Mazzarella, Luca
    Locatelli, Marzia
    Minchella, Ida
    Curigliano, Giuseppe
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (03) : 299 - 305
  • [35] Anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells
    Kishino, E.
    Ogata, R.
    Saitoh, W.
    Koike, Y.
    Ohta, Y.
    Kanomata, N.
    Moriya, T.
    Kurebayashi, J.
    BREAST, 2019, 44 : S28 - S28
  • [36] Follicular Lymphoma Response with CDK4/6 Inhibitor(Palbociclib) Utilized in the Setting of Metastatic Breast Cancer
    Ali, Syed S.
    Mertens, Wilson
    BLOOD, 2017, 130
  • [37] Management of HR-positive, HER2-negative advanced breast cancer with CDK4/6 inhibitors: Effect of online education on clinician knowledge, competence and confidence
    Fisher, G.
    Middleton, D.
    Day, C.
    Di Leo, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S102 - S102
  • [38] Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer
    Hashimoto, Kazuki
    Shimomura, Akihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (13) : 1506 - +
  • [39] Impact of PET and PET/CT Radiotracer for Evaluating Efficacy of CDK4/6 Inhibitor Therapy in HR-Positive HER2-Negative Metastatic Breast Cancer
    Imamovic, Elma
    Veledar, Anisa
    Kalic, Zerina
    Softic, Adna
    Mrdanovic, Emina
    Smajlhodzic-Deljo, Merima
    MEDICON 2023 AND CMBEBIH 2023, VOL 1, 2024, 93 : 345 - 350
  • [40] Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
    Zattarin, Emma
    Presti, Daniele
    Mariani, Luigi
    Sposetti, Caterina
    Leporati, Rita
    Menichetti, Alice
    Corti, Chiara
    Benvenuti, Chiara
    Fuca, Giovanni
    Lobefaro, Riccardo
    Ligorio, Francesca
    Provenzano, Leonardo
    Vingiani, Andrea
    Del Vecchio, Marta
    Griguolo, Gaia
    Sirico, Marianna
    Bernocchi, Ottavia
    Marra, Antonio
    Zagami, Paola
    Agostinetto, Elisa
    Jacobs, Flavia
    Di Mauro, Pierluigi
    Esposito, Andrea
    Giorgi, Carlo Alberto
    Lalli, Luca
    Boldrini, Laura
    Giacchetti, Pier Paolo Berton
    Schianca, Ambra Carnevale
    Guarneri, Valentina
    Pedersini, Rebecca
    Losurdo, Agnese
    Zambelli, Alberto
    Generali, Daniele
    Criscitiello, Carmen
    Curigliano, Giuseppe
    Pruneri, Giancarlo
    de Braud, Filippo
    Dieci, Maria Vittoria
    Vernieri, Claudio
    NPJ BREAST CANCER, 2023, 9 (01)
12345